Status:
TERMINATED
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in pat...
Eligibility Criteria
Inclusion
- Patients giving informed consent
- Patients with a large acute myocardial infarction randomised within 6 hours of symptom onset
- Patients scheduled to undergo primary PCI
- Patients reaching the cath lab not before 60 min and not later than 3 hours after randomisation
- (Otherwise the patients fulfill the usual selection criteria for thrombolytic treatment and PCI)
Exclusion
- None
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
1671 Patients enrolled
Trial Details
Trial ID
NCT00168792
Start Date
November 1 2003
Last Update
October 29 2013
Active Locations (176)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
2
Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
3
Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
4
Boehringer Ingelheim Investigational Site
Tampa, Florida, United States